Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma

Bibliography

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95
   PubMed Web of Science ®Google Scholar
• Levitt M, Marsh JC, Deconti RC, et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 1972;29:630-6
   PubMed Web of Science ®Google Scholar
• Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978;42:1705-10
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Gill D, et al. First analysis of the completed Mabthera International (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease [abstract 157]. Blood 2004;104:48
   Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-9
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappa-B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95
   PubMed Web of Science ®Google Scholar
• Hu L, Hofmann J, Lu Y, et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-92
   PubMed Web of Science ®Google Scholar
• Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1:913-22
   PubMed Web of Science ®Google Scholar
• Zhao MY, Auerbach A, D'Costa AM, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res 2009;15:1708-20
   PubMed Web of Science ®Google Scholar
• Monni O, Barlund M, Mousses S, et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 2001;98:5711-6
   PubMed Web of Science ®Google Scholar
• Grove JR, Banerjee P, Balasubramanyam A, et al. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol 1991;11:5541-50
   PubMed Web of Science ®Google Scholar
• Reinhard C, Thomas G, Kozma SC. A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. Proc Natl Acad Sci USA 1992;89:4052-6
   PubMedGoogle Scholar
• Ferrari S, Thomas G. S6 phosphorylation and the p70s6k/p85s6k. Crit Rev Biochem Mol Biol 1994;29:385-413
   PubMed Web of Science ®Google Scholar
• Burnett PE, Barrow RK, Cohen NA, et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-7
   PubMed Web of Science ®Google Scholar
• Saitoh M, Pullen N, Brennan P, et al. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 2002;277:20104-12
   PubMed Web of Science ®Google Scholar
• Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997;410:78-82
   PubMed Web of Science ®Google Scholar
• Weng QP, Kozlowski M, Belham C, et al. Regulation of the p70S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem 1998;273:16621-9
   PubMedGoogle Scholar
• Kawasome H, Papst P, Webb S, et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. Proc Natl Acad Sci USA 1998;95:5033-8
   PubMed Web of Science ®Google Scholar
• Brown RE, Kamal NR. p-p70S6K (Thr389) expression in nodular sclerosing Hodgkin's disease as evidence for receptor tyrosine kinase signaling. Ann Clin Lab Sci 2005;35:413-4
   PubMedGoogle Scholar
• Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood 2005;106:1911-23
   PubMed Web of Science ®Google Scholar
• Chung J, Grammer TC, Lemon KP, et al. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-5
   PubMed Web of Science ®Google Scholar
• Monfar M, Lemon KP, Grammer TC, et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol Cell Biol 1995;15:326-37
   PubMedGoogle Scholar
• Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 1997;17:338-44
   PubMed Web of Science ®Google Scholar
• Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602
   PubMed Web of Science ®Google Scholar
• Brown EJ, Beal PA, Keith CT, et al. Control of p70S6 kinase by kinase activity of FRAP in vivo. Nature 1995;377:441-6
   PubMed Web of Science ®Google Scholar
• Han JW, Pearson RB, Dennis PB, Thomas G. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem 1995;270:21396-403
   PubMedGoogle Scholar
• Isotani S, Hara K, Tokunaga C, et al. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 1999;274:34493-8
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68
   PubMed Web of Science ®Google Scholar
• Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992;69:1227-36
   PubMed Web of Science ®Google Scholar
• Volarević S, Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001;65:101-27
   PubMedGoogle Scholar
• Avruch J, Belham C, Weng Q, et al. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol 2001;26:115-54
   PubMedGoogle Scholar
• Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999;253:100-9
   PubMed Web of Science ®Google Scholar
• Balendran A, Currie R, Armstrong CG, et al. Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 1999;274:37400-6
   PubMedGoogle Scholar
• Alessi DR, Kozlowski MT, Weng QP, et al. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 1998;8:69-81
   PubMed Web of Science ®Google Scholar
• Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707-10
   PubMed Web of Science ®Google Scholar
• Belham C, Comb MJ, Avruch J. Identification of the NIMA family kinases NEK6/7 as regulators of the p70 ribosomal S6 kinase. Curr Biol 2001;11:1155-67
   PubMedGoogle Scholar
• Romanelli A, Dreisbach VC, Blenis J. Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem 2002;277:40281-9
   PubMedGoogle Scholar
• Gonzalez-Garcia A, Garrido E, Hernandez C, et al. A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70S6 kinase activation. J Biol Chem 2002;277:1500-8
   PubMedGoogle Scholar
• Calvo V, Crews CM, Vik TA, Bierer BE. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci USA 1992;89:7571-5
   PubMed Web of Science ®Google Scholar
• Calvo V, Wood M, Gjertson C, et al. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. Eur J Immunol 1994;24:2664-71
   PubMedGoogle Scholar
• Reif K, Burgering BM, Cantrell DA. Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem 1997;272:14426-33
   PubMed Web of Science ®Google Scholar
• Pearson RB, Thomas G. Regulation of p70s6k/p85s6k and its role in the cell cycle. Prog Cell Cycle Res 1995;1:21-32
   PubMedGoogle Scholar
• Lane HA, Fernandez A, Lamb NJ, Thomas G. p70s6k function is essential for G1 progression. Nature 1993;363:170-2
   PubMed Web of Science ®Google Scholar
• Dhar R, Basu A. Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. Int J Oncol 2008;32:1133-7
   PubMedGoogle Scholar
• Kwon HK, Bae GU, Yoon JW, et al. Constitutive activation of p70S6k in cancer cells. Arch Pharm Res 2002;25:685-90
   PubMedGoogle Scholar
• Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005;205:498-506
   PubMed Web of Science ®Google Scholar
• Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006;108:1668-76
   PubMed Web of Science ®Google Scholar
• Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-97
   PubMed Web of Science ®Google Scholar
• Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006;108:4156-62
   PubMed Web of Science ®Google Scholar
• Harada H, Andersen JS, Mann M, et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001;98:9666-70
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Chung J, Fiorentino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;58:70-3
   Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
   PubMed Web of Science ®Google Scholar
• Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-85
   PubMed Web of Science ®Google Scholar
• Gaben AM, Saucier C, Bedin M, et al. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. Int J Cancer 2004;108:200-6
   PubMed Web of Science ®Google Scholar
• Jundt F, Raetzel N, Müller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-7
   PubMed Web of Science ®Google Scholar
• Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006;134:475-84
   PubMed Web of Science ®Google Scholar
• Lee MG, Nurse P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 1987;327:31-5
   PubMed Web of Science ®Google Scholar
• Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313-20
   PubMed Web of Science ®Google Scholar
• Pines J. Cell cycle. Confirmational change. Nature 1995;376:294-5
   PubMed Web of Science ®Google Scholar
• Stark GR, Taylor WR. Control of the G2/M transition. Mol Biotechnol 2006;32:227-48
   PubMed Web of Science ®Google Scholar
• Jackman M, Firth M, Pines J. Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J 1995;14:1646-54
   PubMed Web of Science ®Google Scholar
• Takizawa CG, Weis K, Morgan DO. Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. Proc Natl Acad Sci USA 1999;96:7938-43
   PubMedGoogle Scholar
• Moore JD, Yang J, Truant R, Kornbluth S. Nuclear import of Cdk/cyclin complexes: identification of distinct mechanisms for import of Cdk2/cyclin E and Cdc2/cyclin B1. J Cell Biol 1999;144:213-24
   PubMed Web of Science ®Google Scholar
• Hagting A, Karlsson C, Clute P, et al. MPF localization is controlled by nuclear export. EMBO J 1998;17:4127-38
   PubMed Web of Science ®Google Scholar
• Yang J, Bardes ES, Moore JD, et al. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev 1998;12:2131-43
   PubMed Web of Science ®Google Scholar
• Fesquet D, Labbé JC, Derancourt J, et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J 1993;12:3111-21
   PubMed Web of Science ®Google Scholar
• Poon RY, Yamashita K, Adamczewski JP, et al. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J 1993;12:3123-32
   PubMed Web of Science ®Google Scholar
• Solomon MJ, Harper JW, Shuttleworth J. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J 1993;12:3133-42
   PubMed Web of Science ®Google Scholar
• Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 1997;17:571-83
   PubMed Web of Science ®Google Scholar
• Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992;257:1955-7
   PubMed Web of Science ®Google Scholar
• Sebastian B, Kakizuka A, Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 1993;90:3521-4
   PubMedGoogle Scholar
• Hui D, Reiman T, Hanson J, et al. Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol 2005;18:1223-31
   PubMed Web of Science ®Google Scholar
• Björck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005;105:2908-15
   PubMed Web of Science ®Google Scholar
• Ito Y, Yoshida H, Matsuzuka F, et al. Cdc2 expression in primary thyroid lymphoma: its relationship with biological aggressiveness and G2 cyclins. Pathol Res Pract 2003;199:533-8
   PubMed Web of Science ®Google Scholar
• Obermann EC, Went P, Pehrs AC, et al. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Oncol Rep 2005;14:1461-7
   PubMed Web of Science ®Google Scholar
• Wang YF, Hsieh YF, Lin CL, et al. Staurosporine-induced G2/M arrest in primary effusion lymphoma BCBL-1 cells. Ann Hematol 2004;83:739-44
   PubMedGoogle Scholar
• Goga A, Yang D, Tward AD, et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007;13:820-7
   PubMed Web of Science ®Google Scholar
• Faber AC, Chiles TC. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle 2007;6:2982-9
   PubMed Web of Science ®Google Scholar
• Ackler S, Xiao Y, Mitten MJ, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008;7:3265-74
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Rahmani M, et al. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 2005;11:4589-600
   PubMed Web of Science ®Google Scholar
• West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updat 2002;5:234-48
   PubMed Web of Science ®Google Scholar
• Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727-38
   PubMed Web of Science ®Google Scholar
• O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54
   PubMed Web of Science ®Google Scholar
• Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008;6(Suppl 5):S1-20
   PubMedGoogle Scholar
• Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-62
   PubMed Web of Science ®Google Scholar